Avior Wealth Management LLC Decreases Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Avior Wealth Management LLC cut its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 12.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 622 shares of the medical instruments supplier’s stock after selling 85 shares during the quarter. Avior Wealth Management LLC’s holdings in West Pharmaceutical Services were worth $204,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of WST. Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services during the third quarter valued at approximately $30,000. Retirement Wealth Solutions LLC purchased a new stake in West Pharmaceutical Services during the 4th quarter valued at $34,000. Brooklyn Investment Group bought a new stake in West Pharmaceutical Services in the 3rd quarter worth $41,000. MassMutual Private Wealth & Trust FSB increased its position in shares of West Pharmaceutical Services by 60.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 209 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 79 shares during the period. Finally, Hilltop National Bank raised its stake in shares of West Pharmaceutical Services by 47.9% during the fourth quarter. Hilltop National Bank now owns 216 shares of the medical instruments supplier’s stock valued at $71,000 after acquiring an additional 70 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Bank of America boosted their price target on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a report on Friday, December 13th. Citigroup began coverage on West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price for the company. UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price target for the company from $350.00 to $390.00 in a report on Thursday, December 12th. Finally, Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and an average price target of $430.20.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $345.15 on Tuesday. The business has a fifty day simple moving average of $329.08 and a two-hundred day simple moving average of $313.54. The firm has a market capitalization of $25.00 billion, a P/E ratio of 51.21, a P/E/G ratio of 18.59 and a beta of 1.00. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.